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Abstract
Context—A subset (~3–5%) of patients with cystic fibrosis (CF) develops severe liver disease
(CFLD) with portal hypertension.
Objective—To assess whether any of 9 polymorphisms in 5 candidate genes (SERPINA1, ACE,
GSTP1, MBL2, and TGFB1) are associated with severe liver disease in CF patients.
Design, Setting, and Participants—A 2-stage design was used in this case–control study.
CFLD subjects were enrolled from 63 U.S., 32 Canadian, and 18 CF centers outside of North
America, with the University of North Carolina at Chapel Hill (UNC) as the coordinating site. In
the initial study, we studied 124 CFLD patients (enrolled 1/1999–12/2004) and 843 CF controls
(patients without CFLD) by genotyping 9 polymorphisms in 5 genes previously implicated as
modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon
10 genotype were tested in an additional 136 CFLD patients (enrolled 1/2005–2/2007) and 1088
CF controls.
Main Outcome Measures—We compared differences in distribution of genotypes in CF
patients with severe liver disease versus CF patients without CFLD.
Results—The initial study showed CFLD to be associated with the SERPINA1 (also known as
α1-antiprotease and α1-antitrypsin) Z allele (P value=3.3×10−6; odds ratio (OR) 4.72, 95%
confidence interval (CI) 2.31–9.61), and with transforming growth factor β-1 (TGFB1) codon 10
CC genotype (P=2.8×10−3; OR 1.53, CI 1.16–2.03). In the replication study, CFLD was associated
with the SERPINA1 Z allele (P=1.4×10−3; OR 3.42, CI 1.54–7.59), but not with TGFB1 codon
10. A combined analysis of the initial and replication studies by logistic regression showed CFLD
to be associated with SERPINA1 Z allele (P=1.5×10−8; OR 5.04, CI 2.88–8.83).
Conclusion—The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry
the Z allele are at greater odds (OR ~5) to develop severe liver disease with portal hypertension.
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Cystic fibrosis (CF) is a recessive monogenic disorder characterized by multi-organ
involvement and clinical heterogeneity that is incompletely explained by mutations within
the cystic fibrosis transmembrane conductance regulator (CFTR) gene.1 Patients with CF,
including those homozygous for DF508, exhibit a range of lung disease severity, and genetic
variability in non-CFTR genes contributes to risk for severity of pulmonary disease.2–7
Intrinsic abnormalities in the CF liver reflect loss of CFTR (Cl− channel) function on the
apical membrane of cholangiocytes.8,9 This dysfunction is predicted to result in defective
(sluggish) bile flow, and is associated with a cholangiocyte-induced inflammatory response
with activation and proliferation of hepatic stellate cells, which results in cholangitis and
fibrosis in focal portal tracts.10–13 However, only a small fraction (~3–5%) of CF patients
develops severe liver disease characterized by cirrhosis with portal hypertension (CFLD)1;
thus, non-CFTR genetic variability may contribute to risk for severe liver disease.14–17
To determine the association between non-CFTR genetic polymorphisms and severe liver
disease in CF with portal hypertension (CFLD), we studied 9 functional variants in 5 genes
previously studied in CF liver disease, including α1-antitrypsin (also known as α1-
antiprotease, α1AP, SERPINA1)18, angiotensin-converting enzyme (ACE)19, glutathione S-
transferase (GSTP1)20, mannose-binding lectin 2 (MBL2)21 and transforming growth factor
β1 (TGFB1).19 Our initial study compared polymorphic genotypes in these candidate
modifier genes in CF subjects with CFLD and “control” CF patients (without CFLD, who
were at least 15 years of age). We tested our initial findings in a second study in different
populations of CF patients with and without CFLD.
METHODS
Patients - Initial (First) Study
Of the 158 CF patients evaluated for severe liver disease (CFLD; portal hypertension;
enrolled 1/1999–12/2004), there were 128 patients who fulfilled criteria from 22 CF Centers
in 10 countries (Australia, 8; Canada, 17; Czech Republic, 17; Germany, 3; Italy, 28;
Netherlands, 1; Scotland, 2; Slovakia, 4; Turkey, 4; and U.S., 44). For patients without 2
defined mutations in CFTR, we tested further, using a panel of 70 mutations (Tm
Bioscience/Luminex CFTR mutation detection assay). After genotyping was complete,
>95% of CFLD patients with 2 defined mutations in CFTR had 2 pancreatic insufficient (PI)
mutations (eTable 1). The 843 control patients (CF patients without CLFD) were enrolled
from the U.S. (759 patients from 42 Centers) and Canada (84 patients from 32 Centers). The
majority of the CF controls were ascertained from the GMS Lung Study population (DF508
homozygotes; 92.6%)5, Most of the other controls had biallelic PI mutations (see online
supplement, Methods). These controls without CFLD were ≥ 15 years of age (1 SD above
the mean age of diagnosis of CFLD), in order to exclude younger patients who might have
occult liver disease.
Patients - Replication (Second) Study
Of the 191 CF patients evaluated for CFLD (portal hypertension; enrolled 1/2005–2/2007),
there were 139 CF patients who fulfilled criteria from 35 CF Centers in 10 countries
(Argentina, 5; Australia, 5; Canada, 24; Chile, 1; France, 9; Ireland, 8; Israel, 7; Italy, 14;
United Kingdom, 4; and U.S., 62). The percentage of PI CFTR genotypes in CFLD subjects
was similar to those in the initial study (eTable 1). The 1088 control patients (CF patients ≥
15 years without CFLD) were ascertained from five countries (Canada, 391 patients from 32
Centers; Czech Republic, 30 patients; Ireland, 6 patients; Italy, 71 patients; and U.S., 590
patients from 54 Centers). The majority of the CF controls had 2 PI mutations (93.5%;
mostly DF508/DF508 62.8%) (online supplement, Methods).
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All patients had a diagnosis of CF, confirmed by sweat test and/or CFTR genotyping. CFLD
was defined as cirrhosis in patients ≥ 2 years of age, confirmed by imaging (ultrasound, CT,
MRI) showing hepatic parenchymal abnormalities of portal hypertension (esophageal
varices, portal-systemic collaterals, splenomegaly) in the absence of another cause for liver
disease. Data were independently reviewed by 2 hepatologists (P.R.D. and S.C.L.) with
experience in CFLD to ensure inclusion and exclusion criteria were met, using case report
forms, radiology and endoscopy reports, and clinical notes. When there was no consensus,
the reviewers requested additional information to clarify the diagnosis of CFLD. No patient
was excluded because of race or ethnic background, which were subject-defined.
We excluded 30 (19%) and 52 (27%) subjects originally submitted for the initial and
replication studies, respectively, with a presumed diagnosis of CFLD, because they had
milder liver disease without portal hypertension, or inadequate documentation. For the 47
patients with confirmed CFLD who had a liver transplant (26 in initial study; 21 in
replication study), source documents were obtained from dates prior to transplant. Exclusion
criteria for the CFLD group included portal vein thrombosis or other causes of liver disease
(alcohol abuse, biliary atresia, clinically significant viral hepatitis, use of parenteral
nutrition, and Wilson disease). The study was approved by the Institutional Review Boards
of all participating institutions and written informed consent was obtained.
Exclusion from Analysis Based on Age of Diagnosis of CFLD
In common with previous reports, we found the mean age of diagnosis of CFLD (first
documentation of portal hypertension) to be 10.6 (± 5.4) years (eFigure 1).15,22–25 The
diagnosis of CFLD was first established after the age of 30 years in 7 subjects (ages of 32,
33, 35, 40, 43, 44, and 47 years), which is ≥ 4 SD above the mean of the normal distribution.
Therefore, these patients were excluded from the genetic analyses (4 from the initial study,
and 3 from the replication study).
Data Collection
Patients received a unique identifier code, and data was stored in a secure database in the
UNC Bioinformatics Center. Clinical data on standard case report forms included self-
reported race/ethnicity, pancreatic exocrine status, medical history, physical examination,
laboratory blood work values, and abdominal radiology reports. In addition, we reviewed the
following procedure reports if available: liver explant pathology (from liver transplant), liver
biopsy, endoscopy and colonoscopy.
DNA Extraction and Genotyping
DNA was extracted from peripheral blood leukocytes using standard protocols.26 Genetic
polymorphisms were determined by direct sequencing, by microsphere-based genotyping
using Illumina BeadArray™ technology (San Diego, CA) and by site-directed mutagenesis
(online supplement, Methods).
Histochemistry/Histopathology
Immunohistochemistry with polyclonal rabbit anti-α-1 antitrypsin antibody and monoclonal
mouse anti-CD68 (clone KP1) antibody (Dako Canada, Ontario, Canada), was performed on
the Benchmark XT™ auto-immunostainer (Ventana Medical Systems, Tucson, AZ) at
dilutions of 1:3000 and 1:5000, respectively. Immunodetection was performed using the
Ventana, i-VIEW DAB, LSAB kit. Tissue sections were dewaxed, enzyme pretreated for
α-1 antitrypsin, heat epitope retrieved for CD68, peroxidase, and endogenous biotin blocked
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using Ventana proprietary reagents. Sections were hematoxylin counterstained for nuclear
detail (eFigure 2).
Statistical Analysis
Genotype distributions were tested for consistency with expected Hardy-Weinberg
equilibrium (HWE) proportions for cases and controls in the initial, replication and
combined studies, using all subjects and then restricted to Caucasian subjects, using the
PLINK software package (version 1.03; http://pngu.mgh.harvard.edu/~purcell/plink/).27
For the initial study, the association between polymorphisms and CFLD was assessed using
Cochran-Armitage trend tests.28 All tests were 2-sided and unadjusted P values are reported,
along with P values that were significant (P<0.05) after Bonferroni (adjusted for 9 tests)
correction (appended to Tables). Analyses were performed using all samples, and only
Caucasian samples.
For the replication study, the association between 2 polymorphisms from the initial study
(SERPINA1 Z allele, and TGFB1 codon 10) and CFLD was assessed using Cochran-
Armitage trend tests. Initial and replication samples were subsequently combined and
analyzed for the SERPINA1 Z allele using Cochran-Armitage trend tests and logistic
regression models (online supplement, Methods). Varying levels of covariate adjustment in
the logistic regression models were made for ethnicity (as a 5-level categorical variable for
all samples), gender, CFTR genotype and TGFB1 codon 10 genotype. Tests of interactions
were performed to assess whether the odds of CFLD differed between males and females by
SERPINA1 genotype. Odds ratios (and corresponding 95% confidence intervals) and
uncorrected P values are reported. Bonferroni correction was applied to assess overall
statistical significance in the replication and combined analyses (adjusting for 2 tests in the
replication and 9 tests in the combined sample). Analyses were performed separately, using
all samples and then using Caucasian subjects only.
Analysis of variance models were used to assess whether gender, SERPINA1 Z allele and
CFTR genotype were associated with age of diagnosis of CFLD in the combined sample.
Data were analyzed on all CFLD cases and Caucasian CFLD cases with a reported age at
diagnosis with covariate adjustment for self-reported ancestry.
To estimate population attributable risk, we used a modified form of Levin’s classic formula
for population attributable fraction by replacing relative risk estimates with odd ratios, and
using the proportion of control subjects carrying the Z allele as an estimate of the probability
of exposure29–31 (online supplement, Methods). While this estimate is not exact, given our
case–control sampling design (over-sampled older CF patients without CFLD), this estimate
should provide a reasonable approximation, due to the modest frequency of CFLD in CF
patients (~5%).
RESULTS
Clinical Features - Initial Study
Characteristics of the initial group of 124 CF patients with severe liver disease and 843 CF
patients without CFLD are shown in Table 1. The CFLD group was younger at enrollment,
had more males, and slightly fewer Caucasians. The CFTR mutations in CFLD patients were
representative of PI mutations in North American and European CF patients (Table 1,
eTable 1)1. The prevalence of meconium ileus at birth in CFLD patients (18.2%) is
comparable to the control (no CFLD) group, and typical for the general CF population with
pancreatic insufficient CFTR mutations.1
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Abnormalities in biochemical tests of the liver (AST, ALT and GGT) were not predictive of
CFLD and showed no correlation with markers of hepatocellular synthetic dysfunction, such
as international normalized ratio (INR) and serum albumin (Table 2). Preoperative
assessment of data available from a subset of patients (n=22) who underwent liver transplant
(n=43) showed a similar distribution of abnormal total bilirubin and, albumin values as the
non-transplanted patients (Table 2, footnote “b” and “c”).
Cochran-Armitage Trend Test of Association – Initial Study
In the analysis of previously studied gene modifiers of liver disease in CF (Table 3),
association was seen only for the SERPINA1 Z allele (P=3.3×10−6; OR 4.72, CI 2.31–9.61)
andTGFB1 codon 10 (P=2.8×10−3; OR 1.53, CI 1.16–2.03). The SERPINA1 Z allele
displayed association for all CFLD patients, but was more prominent in females (eTable 2).
Similar results were seen when the analysis was restricted to Caucasians (data not shown). It
is noteworthy that small effects for the non-significant polymorphisms would not be
detected with sufficient power by this study (see online supplement Methods – Power
Analysis; eTable 3). The genotypes and minor allele frequencies for genetic variants in
patients without CFLD were similar to those previously reported.5–7,18–21
Clinical Features - Replication Study
Based on the associations for the SERPINA1 Z allele and TGFB1 codon 10 (Table 3), we
enrolled additional CF patients with and without CFLD to test for replication (Table 4). The
characteristics of the replication patients were similar to those in the initial study (Table 1),
including the distribution of specific CFTR mutations (eTable 1), prevalence of meconium
ileus (23.8%) and liver function abnormalities (Table 2, Table 4).
Cochran-Armitage Trend Test of Association – Replication Study
The association was replicated for the SERPINA1 Z allele (P=1.4×10−3; OR 3.42, CI 1.54–
7.59); Table 5), but the association was more prominent in males (eTable4), in contrast to
the initial study (eTable 2). Similar results were seen when analyses were restricted to
Caucasians (data not shown). The association of the TGFB1 codon 10 variant was not
replicated for all patients (Table 5) or for males or females when analyzed separately (data
not shown).
Cochran-Armitage Trend Test of Association – Initial plus Replication Study
When the initial and replication populations were combined for analysis using Cochran-
Armitage trend tests, the SERPINA1 Z allele displayed very robust association with CFLD
(P=9.9×10−9; OR 4.17, CI 2.46–7.05 eTable 4); similar evidence for association was
observed in analyses restricted to Caucasian subjects in the initial plus replication
populations(data not shown ).
Hardy-Weinberg Equilibrium
All polymorphisms had genotype distributions consistent with Hardy-Weinberg equilibrium
(P > 0.01) in the initial, replication, and combined samples, irrespective of how samples
were partitioned according to ethnicity and CFLD status.
Logistic Regression for the Z Allele – Initial plus Replication Study
We combined the initial and replication groups and performed logistic regression for the
SERPINA1 Z allele to estimate the odds of CFLD, adjusting for the covariates of ethnicity,
gender and CFTR genotype. Results remained consistent when using all subjects or
Caucasian subjects only, with respect to both statistical significance estimates (P=1.5×10−8
or P=6.3×10−8, respectively) and odds ratio estimates (OR 5.04, CI 2.88–8.83 for all patients
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vs. OR 4.87, CI 2.75–8.64 for Caucasians only). In addition, we saw no evidence for
interactions between gender and the SERPINA1 Z allele in all subjects or only Caucasians.
Similar results were obtained by logistic regression adjusting only for ethnicity in the
complete sample, and models that additionally adjusted for the TGFB1 codon 10 genotype
(eTable 5).
Population Attributable Risk
We combined the initial and replication groups, and the population attributable risk for the Z
allele was estimated to be 6.7% (Caucasians only, 6.6%) (see online supplement, Methods).
A similar result was obtained using another method of estimating the probability of
exposure, namely the average Z allele frequency of patients from North America, Europe
and Australia (data not shown).
Age of Diagnosis of CFLD
The mean and median age of recognition (diagnosis) of portal hypertension in all CFLD
patients was ~10–11 years (eFigure 1) and 90% of patients had CFLD diagnosed before 20
years of age. Males had an earlier age of diagnosis of CFLD than females for all subjects
(males=8.5 yrs, females=10.5 years; P=0.007), and for self-reported Caucasians (males=9.7
years, females=11.5 years; P=0.027). Age at diagnosis of CFLD was not associated with the
presence of the SERPINA1 Z allele, CFTR genotype or self-reported ancestry.
Liver Histopathology
A CFLD subject carrying a single copy of the SERPINA1 Z allele accumulated SERPINA1
protein within hepatocytes adjoining the fibrosed portal tracts, but SERPINA1 protein is not
seen in hepatocytes of a CFLD patient without the Z allele (eFigure 2).
COMMENT
Previous studies have suggested that genetic polymorphisms may act as modifiers of liver
disease in cystic fibrosis, but these studies were small and phenotyping did not address the
development of severe (biliary) cirrhosis associated with portal hypertension.18–21 To
increase the likelihood of identifying genetic modifiers that are relevant to the development
of severe liver disease in CF, i.e., cirrhosis with portal hypertension, we performed 2
sequential studies in different groups of patients. The initial study involved 5 candidate
genes that had previously been studied as modifiers of CF liver disease18–21, and the
replication study tested for confirmation of SERPINA1 Z allele and TGFB1 codon 10
variant as modifiers of severe liver disease in CF.
This study had 3 key design features. First, we used rigorous criteria to identify CF patients
with portal hypertension (“cases”), reflecting hepato-biliary cirrhosis, and key source
documents were reviewed independently by 2 experts to confirm the CFLD phenotype.
Second, for CF patients without CFLD (“controls”), we studied only patients who were ≥ 15
years of age, in order to exclude younger patients with predisposition to develop CFLD.
Third, we enrolled a large number of CF patients with and without CFLD in order to
improve statistical power. For the initial study, ~50% of the CFLD patients were from
outside North America and 93% were self-described as Caucasian, and all control CF
patients were from North America. For the replication (second) study, a slightly greater
percentage of CFLD patients were from North America (63% versus 50%), and there were
some control CF patients (10%) from outside North America.
Genetic analyses of the initial cohort showed that a single copy of the SERPINA1 Z allele
and each additional copy of the TGFB1 codon 10 C allele were associated with significantly
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increased odds of CFLD. In the replication study, the SERPINA1 Z allele was confirmed as
a modifier of liver disease in CF, whereas the TGFB1 codon 10 variant was not confirmed.
It is noteworthy that small effects of the non-significant polymorphisms in other genes
would not be detected with sufficient power by this study. The association of the SERPINA1
Z allele with CFLD contrasts to a previous “negative” study, which used less stringent
phenotypic markers of CF liver disease, such as liver function tests, which do not correlate
with severity of CFLD (portal hypertension).18
When the initial and replication study populations were combined for joint analysis by
multivariable logistic regression, the magnitude of the effect of the SERPINA1 Z allele was
large compared to most genetic association studies (odds ratio ~5) when gender, ethnicity
and CFTR genotype were included as covariates. The strength of the association of the
SERPINA1 Z allele with CFLD varied by gender for the initial versus the replication
studies, but the overall odds were not statistically different for females and males when all
subjects were analyzed. Population stratification is unlikely to account for the results for the
SERPINA1 Z allele; the prevalence of the Z allele (1.14%) in our CF patients without CFLD
(controls) is similar to that reported for > 85,000 individuals genotyped in pertinent regions
of the world (1.20%).32,33 (eFigure 3 and eTable 4).
The mechanism of the SERPINA1 Z allele as an adverse modifier of liver disease in CF
patients likely reflects the dual stimulation of hepatic stellate cells by inflammatory
mediators from both CFTR-deficient cholangiocytes and hepatocytes containing the
misfolded SERPINA1 protein, i.e., these inflammatory stimuli induce hepatic stellate cells
to migrate and proliferate in the bile duct regions in a pro-fibrogenic manner.10–13,16,34–38
Bile duct ligation with resultant cholestasis induces more activated stellate cells and fibrosis
in the liver of homozygous transgenic PiZ versus wild-type mice, which is compatible with
this proposed mechanism of the Z allele as an adverse modifier in CF.39 Further studies are
necessary to better define the pathogenesis of the Z allele in CFLD.
The Z allele variant causes misfolding of the SERPINA1 protein, which results in an
accumulation of protein in hepatocytes. The most prevalent CFTR mutation, DF508, is also
a misfolding mutation, expressed predominantly in cholangiocytes in the liver.8–13,34–38
However, it is unlikely that folding mutations in CFTR and SERPINA1 induce an amplified,
adverse effect on the proteosomal degradation pathway, because these 2 genes are
predominantly expressed in 2 different cell types in the liver.8,9,34–38 Furthermore,
heterozygosity for the Z allele is associated with the risk and progression of a variety of liver
diseases, including cryptogenic cirrhosis, biliary atresia, viral hepatitis, alcoholic cirrhosis
and non-alcoholic fatty liver disease.37,38,40
By studying a large number of CF patients with well-defined severe liver disease and portal
hypertension, we confirmed and refuted some previous observations and discovered new
information about the clinical features of these patients. We confirmed that 1) CFLD is more
common, and diagnosed earlier, in males; 2) specific CFTR mutations do not correlate with
CFLD, but CFTR mutations with residual function (pancreatic sufficient mutations) are
uncommon in subjects with CFLD; 3) hepatic synthetic function is preserved for long
durations in most CFLD patients; 4) thrombocytopenia due to hypersplenism is common in
subjects with portal hypertension due to CFLD; 5) liver biochemical tests are poorly
predictive of severe liver disease and portal hypertension in CF and 6) severe liver disease
(portal hypertension) develops in pediatric patients by age 10–12 years.14–17,22–25 In
addition, we made a striking observation about the age distribution of diagnosis of severe
liver disease, whereby the prevalence of severe liver disease does not increase in CF adults,
despite progressive increase in longevity; more than 90% of our CFLD patients were
diagnosed by age 20, with a mean (and median) age of diagnosis of 10–11 years. We were
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not able to confirm any association of meconium ileus with CFLD, as previously reported in
some, but not all, studies;15–17,22–25,41 the prevalence of meconium ileus in our patients with
CFLD (~20%) was similar to that reported for pancreatic exocrine insufficient patients.1
In summary, we studied 2 large populations of CF patients with and without liver disease
and portal hypertension in order to test genes previously studied as modifiers of liver
disease. Of these candidate genes, only the SERPINA1 Z allele was significantly associated
with CFLD and portal hypertension. This polymorphism is relatively uncommon in CF
(~2.2% of CF patients are carriers), but the odds ratio for association with severe liver
disease is relatively high (~5) for the contribution of a genetic modifier to a Mendelian
disorder. Moreover, the estimated population attributable risk among CF patients is 6.7%.
From a clinical perspective, a rare variant with large penetrance (such as the Z allele) may
be more useful than a common variant with low penetrance, to screen for genetic
polymorphisms. The availability of this first marker, SERPINA1 Z allele, for the
development of severe liver disease in CF illustrates the possibility of identifying risk
factors in CF patients early in life, conceptually as a secondary component of neonatal
screening after the diagnosis of CF is confirmed.
Supplementary Material
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Table 1









  Mean (± SD) 19.8 (± 7.3) 26.7 (± 9.6)
  Median 18.8 23.3
Gender (male) 88 (71.0%) 462 (54.8%)
Caucasian 115 (92.7%) 822 (97.5%)
Genotype b
  PI/PI c 100 (80.7%) 836 (99.2%)
  PI/PS c 5 (4.0%) 0 (0.0%)
  PS/PS 0 (0.0%) 0 (0.0%)
  PI/unknown 16 (12.9%) 7 (0.8%)
  unknown/unknown 3 (2.4%) 0 (0.0%)
Meconium ileus d 22 (18.2%) 68 (16.5%)
Age of diagnosis of portal hypertension (yrs) e
  Mean (± SD) 10.3 (± 5.9) N/A
  Median 10 N/A
  Range 0.5 – 26 N/A
Portal hypertension documented by f
  Splenomegaly 120 (97.1%) N/A
  Varices (esophageal, rectal) 93 (74.6%) N/A
  Hypersplenism g 69 (62.7%) N/A
a
Age at time of enrollment.
b
CFTR mutations for CFLD patients in initial study: DF508/DF508 56.5%; DF508/PI 19.4%; DF508/unknown 10.5%; PI/PI 4.8%; PI/unknown
2.4%; PI/PS 4.0%; unknown/unknown 2.4%. CFTR mutations for CF no LD patients in initial study: DF508/DF508 92.6%; DF508/PI 5.9%;
DF508/unknown 0.7%; PI/PI 0.7%; PI/unknown 0.1%. See eTable 1 for specific CFTR genotypes for CFLD patients.
c
PI = Pancreatic exocrine insufficient mutation, PS = Pancreatic exocrine sufficient mutation.
d
Data available from 121 CFLD patients (ages 0–26 years) and 411 CF no LD patients (ages 15–28 years).
e
Data available from 122 CFLD patients.
f
Documented using several different imaging techniques; some patients had portal hypertension confirmed by more than one method; all patients
tested had findings compatible with multi-lobular cirrhosis.
g
As defined by platelet count < 100,000/ul; data available on 110 patients.
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Table 4









  Mean (± SD) 18.2 (± 6.2) 27.2 (± 9.2)
  Median 16.6 25.0
Gender (male) 82 (60.3%) 566 (52.0%)
Caucasian 125 (91.9%) 1066 (98.0%)
Genotype b
  PI/PI c 116 (85.4%) 1017 (93.5%)
  PI/PS c 4 (2.9%) 13 (1.2%)
  PS/PS 0 (0.0%) 2 (0.2%)
  PI/unknown 14 (10.3%) 44 (4.0%)
  unknown/unknown 2 (1.4%) 12 (1.1%)
Meconium ileus d 31 (23.8%) 62 (18.3%)
Age of diagnosis of portal hypertension (yrs) e
  Mean (± SD) 11.0 (± 4.7) N/A
  Median 11 N/A
  Range 0.5 – 28 N/A
Portal hypertension documented by f 
  Splenomegaly 124 (91.1%) N/A
  Varices (esophageal, rectal) 101 (74.2%) N/A
  Hypersplenism g 52 (44.4%) N/A
a
Age at time of enrollment.
b
CFTR mutations for CFLD patients in replication study: DF508/DF508 45.6%; DF508/PI 32.4%; DF508/unknown 9.6%; PI/PI 7.4%; PI/
unknown 0.7%; PI/PS 2.9%; unknown/unknown 1.4%. CFTR mutations for CF no LD patients in replication study: DF508/DF508 62.8%; DF508/
PI 27.5%; DF508/PS 0.6%; DF508/unknown 3.7%; PI/PI 3.1%, PI/unknown 0.4%, PI/PS 0.6%; PS/PS 0.2%; unknown/unknown 1.1%. See eTable
1 for specific CFTR genotypes for CFLD patients.
c
PI = Pancreatic exocrine insufficient mutation, PS = Pancreatic exocrine sufficient mutation.
d
Data available from 130 CFLD patients (ages 0–28 years) and 339 CF no LD patients (ages 15–28 years).
e
Data available from 120 CFLD patients.
f
Documented using several different imaging techniques; some patients had portal hypertension confirmed by more than one method; all patients
tested had findings compatible with multi-lobular cirrhosis.
g
As defined by platelet count < 100,000/ul; data available on 117 patients.
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